Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions : Role of the Akt-pathway, glucose transport and HIF-1α

Fleming, Ian NeilAndriu, AlexandraSmith, Timothy Andrew Davies2014-11-292014-11-292014-04-01Fleming, I N, Andriu, A & Smith, T A D 2014, 'Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions : Role of the Akt-pathway, glucose transport and HIF-1α', Breast Cancer Research and Treatment, vol. 144, no. 4, pp. 241-248. https://doi.org/10.1007/s10549-014-2858-10167-6806ORCID: /0000-0001-9505-6418/work/86450261http://hdl.handle.net/2164/4034Acknowledgment The work was funded by the University of Aberdeen and Friends of Anchor. We thank Dr Iain Brown, University of Aberdeen, for the generous gift of the anti-pHER2 antibody.815713681571368engSDG 3 - Good Health and Well-being[18F]FDGglucose transportPI3/AKTtrastuzumabRC0254 Neoplasms. Tumors. Oncology (including Cancer)RC0254Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions : Role of the Akt-pathway, glucose transport and HIF-1αJournal article10.1007/s10549-014-2858-11444